The US Centers for Disease Control and Prevention (CDC) has formally recommended use of BNT/162b2/Comirnaty - the coronavirus vaccine developed by BioNTech (Nasdaq: BNTX) and Pfizer (NYSE: PFE) - in adolescents.
The decision comes days after the US regulator expanded the emergency use authorization (EUA) for the jab to include 12 to 15 year olds, based on clinical data proving safety and efficacy in this age group.
The CDC's Advisory Committee on Immunization Practices (ACIP) voted unanimously on Wednesday to endorse the broader use of the product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze